Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


02 mayo 2013

STROKE. Clinical Sciences. White-Coat and Masked Hypertension Are Associated With Carotid Atherosclerosis in a General Population

Masayo Fukuhara, MD, PhD; Hisatomi Arima, MD, PhD; Toshiharu Ninomiya, MD, PhD; Jun Hata, MD, PhD; Yoichiro Hirakawa, MD, PhD; Yasufumi Doi, MD, PhD; Koji Yonemoto, PhD; Naoko Mukai, MD, PhD; Masaharu Nagata, MD, PhD; Fumie Ikeda, MD, PhD; Kiyoshi Matsumura, MD, PhD; Takanari Kitazono, MD, PhD; Yutaka Kiyohara, MD, PhD

Background and Purpose: On the basis of combined measurements of clinic blood pressure (CBP) and home blood pressure (HBP), blood pressure status can be divided into normotension, white-coat hypertension (WCHT), masked hypertension (MHT), and sustained hypertension (SHT). Despite the clear impact of MHT and SHT on clinical and subclinical arterial disease, uncertainty about the influence of WCHT remains. The objective of this study was to investigate the associations of WCHT, MHT, and SHT with carotid atherosclerosis in a general population.

30 abril 2013

STROKE. Clinical Sciences. Comparison of Risk-scoring Systems in Predicting Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis

Sheng-Feng Sung, MD; Solomon Chih-Cheng Chen, MD, PhD; Huey-Juan Lin, MD, MPH; Yu-Wei Chen, MD; Mei-Chiun Tseng, PhD; Chih-Hung Chen, MD

Background and Purpose: Various risk score models have been developed to predict symptomatic intracerebral hemorrhage (SICH) after intravenous thrombolysis for acute ischemic stroke. In this study, we aimed to determine the prediction performance of these risk scores in a Taiwanese population

16 mayo 2013

STROKE. Clinical Sciences. New Generation of Flow Diverter (Surpass) for Unruptured Intracranial Aneurysms. A Prospective Single-Center Study in 37 Patients

Joost De Vries, MD, PhD; Jeroen Boogaarts, MD; Anouk Van Norden, MD, PhD; Ajay K. Wakhloo, MD, PhD

Background and Purpose: In patients harboring intracranial aneurysms, the major goal in treatment is to prevent bleeding. A new generation of an endoluminal device (Surpass Flow Diverter [Surpass]) was developed to reconstruct parent artery and occlude the aneurysm. We present our clinical and angiographic single-center experience.

30 abril 2013

STROKE. Clinical Sciences. External Validation of the SEDAN Score for Prediction of Intracerebral Hemorrhage in Stroke Thrombolysis

Michael V. Mazya, MD; Paolo Bovi, MD, PhD; José Castillo, MD, PhD; Dalius Jatuzis, MD, PhD; Adam Kobayashi, MD, PhD; Nils Wahlgren, MD, PhD; Niaz Ahmed, MD, PhD

Background and Purpose: The SEDAN score is a prediction rule for assessment of the risk of symptomatic intracerebral hemorrhage (SICH) per the European Cooperative Acute Stroke Study (ECASS) II definition in patients with acute ischemic stroke treated with intravenous thrombolysis. We assessed the performance of the score in predicting SICH per the ECASS II and Safe Implementation of Treatments in Stroke Monitoring Study (SITS-MOST) definitions in the SITS–International Stroke Thrombolysis Register (SITS-ISTR).

01 julio 2014

AMERICAN HEART JOURNAL. Preprocedural statin use in patients undergoing percutaneous coronary intervention

Mohamad Kenaan, MD, Milan Seth, MS, Herbert D. Aronow, MD, Joseph Naoum, MD, Douglas Wunderly, MD, James Mitchiner, MD, Mauro Moscucci, MD, Hitinder S. Gurm, MD, Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)

Background: Earlier studies suggest that administering statins prior to percutaneous coronary interventions (PCIs) is associated with lower risk of periprocedural myocardial infarction and contrast-induced nephropathy. Current American College of Cardiology/American Heart Association guidelines recommend routine use of statins prior to PCI. It is unclear how commonly this recommendation is followed in clinical practice and what its effect on outcomes is.

15 junio 2014

THE AMERICAN JOURNAL OF CARDIOLOGY. Effect of Sustaining Lifestyle Modifications (Nonsmoking, Weight Reduction, Physical Activity, and Mediterranean Diet) After Healing of Myocardial Infarction, Percutaneous Intervention, or Coronary Bypass (from the REasons for Geographic and Racial Differences in Stroke Study)

John N. Booth III, MS, Emily B. Levitan, DSc, Todd M. Brown, MD, MSPH, Michael E. Farkouh, MD, Monika M. Safford, MD, Paul Muntner, PhD

Guidelines recommend lifestyle modification for patients with coronary heart disease (CHD). Few data demonstrate which lifestyle modifications, if sustained, reduce recurrent CHD and mortality risk in cardiac patients after the postacute rehabilitation phase. We determined the association between ideal lifestyle factors and recurrent CHD and all-cause mortality in REasons for Geographic and Racial Differences in Stroke study participants with CHD (n = 4,174). Ideal lifestyle factors (physical activity ≥4 times/week, nonsmoking, highest quartile of Mediterranean diet score, and waist circumference <88 cm for women and <102 cm for men) were assessed through questionnaires and an in-home study visit. There were 447 recurrent CHD events and 745 deaths over a median 4.3 and 4.5 years, respectively. After multivariable adjustment, physical activity ≥4 versus no times/week and non-smoking versus current smoking were associated with reduced hazard ratios (HRs; 95% confidence interval [CI]) for recurrent CHD (HR 0.69, 95% CI 0.54 to 0.89 and HR 0.50, 95% CI 0.39 to 0.64, respectively) and death (HR 0.71, 95% CI 0.59 to 0.86 and HR 0.53, 95% CI 0.44 to 0.65, respectively). The multivariable-adjusted HRs (and 95% CIs) for recurrent CHD and death comparing the highest versus lowest quartile of Mediterranean diet adherence were 0.77 (95% CI 0.55 to 1.06) and 0.84 (95% CI 0.67 to 1.07), respectively. Neither outcome was associated with waist circumference. Comparing participants with 1, 2, and 3 versus 0 ideal lifestyle factors (non-smoking, physical activity ≥4 times/week, and highest quartile of Mediterranean diet score), the HRs (and 95% CIs) were 0.60 (95% CI 0.44 to 0.81), 0.49 (95% CI 0.36 to 0.67), and 0.38 (95% CI 0.21 to 0.67), respectively, for recurrent CHD and 0.65 (95% CI 0.51 to 0.83), 0.57 (95% CI 0.43 to 0.74), and 0.41 (95% CI 0.26 to 0.64), respectively, for death. In conclusion, maintaining smoking cessation, physical activity, and Mediterranean diet adherence is important for secondary CHD prevention.

18 abril 2013

STROKE. Clinical Sciences. Coronary Artery Disease and Risk of Major Vascular Events After Cerebral Infarction

Pierre Amarenco, MD; Philippa C. Lavallée, MD; Julien Labreuche, BS; Gregory Ducrocq, MD; Jean-Michel Juliard, MD, PhD; Laurent Feldman, MD, PhD; Lucie Cabrejo, MD; Elena Meseguer, MD; Céline Guidoux, MD; Valérie Adraï, MD; Samina Ratani, MD; Jérôme Kusmierek, MD; Bertrand Lapergue, MD, PhD; Isabelle F. Klein, MD, PhD; Fernando Gongora-Rivera, MD; Arturo Jaramillo, MD; Halim Abboud, MD; Jean-Marc Olivot, MD, PhD; Mikael Mazighi, MD, PhD; Pierre-Jean Touboul, MD; Philippe Gabriel Steg, MD

Background and Purpose: The impact of asymptomatic coronary artery disease on the risk of major vascular events in patients with cerebral infarction is unknown.

05 abril 2013

STROKE. Interventional Treatment of Acute Ischemic Stroke. Devices and Clinical Trials

Joseph P. Broderick, MD

In an ideal world, our decision to enroll patients in clinical trials would be based on thoughtful, rational, informed, and balanced considerations of available and relevant scientific and clinical data. In reality, our decision making is based more often on our recent clinical experience and the opinions of those clinicians we value. To increase the appropriate and thoughtful enrollment of patients into clinical trials, it is helpful to examine how we make these decisions and the limitations of equipoise as a decision-making tool.

09 abril 2013

STROKE. Interventional Treatment of Acute Ischemic Stroke. The Evolution of Technology

Jeffrey L. Saver, MD

The historical development of technologies for catheter-based reperfusion of the acutely ischemic human brain is brief but eventful (Table). The first clinical patients were treated with local microcatheter delivery of intra-arterial fibrinolytics in the mid-1990s. The first mechanical recanalization technique, primary intra-arterial balloon angioplasty, was described a few years later. Over the subsequent decade and a half, successive waves of innovative mechanical thrombectomy devices were introduced. The rapid proliferation of technology reflects the inherent dynamic of biomechanical device development, characterized by rapid engineering innovation focused on a well-circumscribed target, in contrast to the slower, more deliberate arc of drug development, which requires extensive testing of each new molecular entity for unexpected off-target effects on diverse organs.

26 febrero 2013

STROKE. Interventional and New Approaches to Stroke Prevention. Intracranial Stenting

Colin P. Derdeyn, MD; David Fiorella, MD, PhD; Michael J. Lynn, MS; Tanya N. Turan, MD; Bethany F. Lane, RN; L. Scott Janis, PhD; Marc I. Chimowitz, MB, ChB

The Stenting and Aggressive Medical management for the Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial established aggressive medical management as superior to angioplasty and stenting for symptomatic intracranial atherosclerotic disease. This presentation addresses some criticisms of the trial, emphasizes key knowledge gained from the study and proposes potential new directions for research in this area. At present, the data from the trial are limited to complete 30-day outcomes for all enrolled patients and follow-up to 1 year in approximately half of the cohort.1 Enrollment was stopped early at the recommendation of the Data and Safety Monitoring Board because of higher than expected 30-day complication rates in the stenting arm and a futility analysis indicating essentially no chance that stenting would be proven superior. A total of 451 patients (59% of the target) had been enrolled, with 227 randomized to aggressive medical management alone and 224 to aggressive medical management plus stenting. Follow-up was completed in March 2013 and study close-out is underway. Presentation of the final primary results is planned for the Fall of 2013.

01 junio 2014

NEUROSURGERY. Real-Time Magnetic Resonance-Guided Stereotactic Laser Amygdalohippocampotomy for Mesial Temporal Lobe Epilepsy

Willie, Jon T. MD*,‡,‖; Laxpati, Nealen G. BS*,#; Drane, Daniel L. PhD‡,**; Gowda, Ashok PhD††; Appin, Christina MD§; Hao, Chunhai MD§; Brat, Daniel J. MD, PhD§; Helmers, Sandra L. MD‡; Saindane, Amit MD¶,‖; Nour, Sherif G. MD¶,‖; Gross, Robert E. MD*,‡,‖,#

Background: Open surgery effectively treats mesial temporal lobe epilepsy, but carries the risk of neurocognitive deficits, which may be reduced with minimally invasive alternatives.

01 mayo 2014

NEUROSURGERY. Resting-State Functional Magnetic Resonance Imaging: Review of Neurosurgical Applications

Lang, Stefan MD*; Duncan, Niall PhD‡,§; Northoff, Georg MD, PhD‡

Recent research in brain imaging has highlighted the role of different neural networks in the resting state (ie, no task) in which the brain displays spontaneous low-frequency neuronal oscillations. These can be indirectly measured with resting-state functional magnetic resonance imaging, and functional connectivity can be inferred as the spatiotemporal correlations of this signal. This technique has proliferated in recent years and has allowed the noninvasive investigation of large-scale, distributed functional networks. In this review, we give a brief overview of resting-state networks and examine the use of resting-state functional magnetic resonance imaging in neurosurgical contexts, specifically with respect to neurooncology, epilepsy surgery, and deep brain stimulation. We discuss the advantages and disadvantages compared with task-based functional magnetic resonance imaging, the limitations of resting-state functional magnetic resonance imaging, and the emerging directions of this relatively new technology.

01 junio 2014

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Vascular Medicine. A Critical Role for the Vascular Endothelium in Functional Neurovascular Coupling in the Brain

Brenda R. Chen, PhD; Mariel G. Kozberg, MPhil; Matthew B. Bouchard, PhD; Mohammed A. Shaik, BS; Elizabeth M. C. Hillman, PhD

Background: The functional modulation of blood flow in the brain is critical for brain health and is the basis of contrast in functional magnetic resonance imaging. There is evident coupling between increases in neuronal activity and increases in local blood flow; however, many aspects of this neurovascular coupling remain unexplained by current models. Based on the rapid dilation of distant pial arteries during cortical functional hyperemia, we hypothesized that endothelial signaling may play a key role in the long‐range propagation of vasodilation during functional hyperemia in the brain. Although well characterized in the peripheral vasculature, endothelial involvement in functional neurovascular coupling has not been demonstrated.

01 junio 2014

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Stroke. Clinical Prediction Model Suitable for Assessing Hospital Quality for Patients Undergoing Carotid Endarterectomy

Neil J. Wimmer, MD; John A. Spertus, MD, MPH; Kevin F. Kennedy, MS; H. Vernon Anderson, MD; Jeptha P. Curtis, MD; William S. Weintraub, MD; Mandeep Singh, MD, MPH; John S. Rumsfeld, MD, PhD; Frederick A. Masoudi, MD, MSPH; Robert W. Yeh, MD, MSc

Background: Assessing hospital quality in the performance of carotid endarterectomy (CEA) requires appropriate risk adjustment across hospitals with varying case mixes. The aim of this study was to develop and validate a prediction model to assess the risk of in‐hospital stroke or death after CEA that could aid in the assessment of hospital quality.

01 junio 2014

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Stroke. Atrial Fibrillation, Stroke, and Anticoagulation in Medicare Beneficiaries: Trends by Age, Sex, and Race, 1992–2010

Gautam R. Shroff, MBBS; Craig A. Solid, PhD; Charles A. Herzog, MD, FAHA

Background: We evaluated temporal trends in ischemic stroke and warfarin use among demographic subsets of the US Medicare population that are not well represented in randomized trials of warfarin for stroke prevention in nonvalvular atrial fibrillation (AF).

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.